Background and Aims: Patients with active, steroid-dependent ulcerative colitis with insufficient response or intolerance to immunosuppressants and/or biologic therapies have limited treatment options. Adacolumn, a granulocyte/monocyte adsorptive apheresis device, has shown clinical benefit in these patients. This study aimed to provide additional clinical data regarding the safety and efficacy of Adacolumn in this patient subgroup. The ART Trial: 12-week Interim Results
Introduction
Ulcerative colitis [UC] is a chronic relapsing and remitting inflammatory condition of the colon affecting between 1 and 20 people per 100 000 population per year. 1, 2 Relapses present with symptoms such as abdominal pain, bloody diarrhoea, weight loss, and anaemia, all of which have a significant impact on quality of life. 2 The therapeutic goal of UC treatments is to induce steroid-free clinical remission, 3 with remission defined as the complete resolution of symptoms; a response to treatment is defined as clinical improvement. 2 Treatment typically follows an escalation or stepup approach whereby additional therapies are added in order to induce and maintain remission. 3, 4, 5 There is, however, an urgent need for therapies for steroid-dependent and steroid-refractory moderate-to-severely active UC patients due to side effects, patient intolerance to existing treatments, and failure of previous treatments. After the failure of existing therapies, surgery is often the only remaining option for these patients. 3 In this context, granulocyte and monocyte adsorptive [GMA] apheresis [Adacolumn ® , Otsuka Pharmaceuticals] and granulocytapheresis [GCAP; Cellsorba ® , Asahi Medical] have emerged as nonpharmacological treatments with few side effects. 6, 7, 8 The mechanism of action of GMA apheresis consists of the selective removal of the cell populations involved in the induction and perpetuation of bowel inflammation from the peripheral blood [neutrophils, monocytes, and platelets] without affecting other cells such as lymphocytes and erythrocytes. 9 GMA has also been shown to modulate levels of proinflammatory cytokines such as TNF-α, interleukin [IL]-1β, IL-6, and IL-8, and reduces cell-surface levels of L-selectin, a molecule that plays a key role in initiating leukocyte adhesion to the vascular endothelium. 10, 11 The clinical efficacy of GMA apheresis has been demonstrated in several studies, with clinical remission and response rates comparable to those seen with conventional therapies. 12, 13, 14 Registry data have shown that in clinical practice, apheresis leads to long-term steroid-free clinical remission in up to one-third of steroid-dependent UC patients. 15 An open-label multicentre study of 39 patients with steroid-refractory chronic active UC found that five apheresis sessions with Adacolumn resulted in a 37.1% clinical remission rate at Week 6, with 28.6% of patients achieving endoscopic remission. The median total dose of systemic steroids decreased from 20.0 mg/ day at baseline to 15 16 Further clinical data on Adacolumn in difficult-to-treat UC patients are, however, required in order to fully explore the role of this device in the management of patients for whom clinical guidelines do not provide additional guidance due to limited treatment options.
The ART study was designed to further evaluate the effectiveness and safety of Adacolumn in patients with moderate-to-severe UC who had an inadequate response to, or lost response to, or were intolerant to immunosuppressants and/or a biologic therapy. We report here the 12-week interim results of the 96-week ART study.
Methods

Study design
The ART [Adacolumn in Refractory UC Patients Trial] study is a single-arm, open-label, multicentre, post-marketing device study [NCT01481142] conducted at 18 centres across the UK, France, and Germany in accordance with the guidelines established in the Declaration of Helsinki. ART is a 96-week study, consisting of a 5-week treatment period and an additional optional 5-week treatment period, with study evaluations at Weeks 12, 24, and 48, and an additional telephone contact at Week 96 [ Figure 1a ].
Patient population
Eligible patients were 18 to 75 years old with moderate-to-severe, steroid-dependent, refractory active UC with insufficient response or intolerance to immunosuppressants and/or biologic agents. Insufficient response was defined as clinical activity index [CAI] ≥ 6 after 3 months of treatment with 2.5 mg/kg azathioprine or 1.5 mg/ kg 6-mercaptopurine or after 14 weeks of starting anti-TNF-α therapy. Intolerance to previous therapies was defined as an allergic reaction, pancreatitis, severe immunosuppression, a psychotic disorder, or any contraindication according the manufacturer's package insert.
UC was documented by clinical symptoms, endoscopic findings, and histology. Disease severity and steroid dependence were defined according to the ECCO guidelines. 2 Key inclusion criteria were UC CAI ≥ 6 and endoscopic activity index [EAI] ≥ 4, 17 and adequate peripheral venous access for the completion of apheresis.
Exclusion criteria included history of hypercoagulation disorder, hypersensitivity or intolerance to apheresis procedures, heparin allergy, or previous heparin-induced thrombocytopenia.
Patients were required to give written informed consent before undergoing any study procedures.
Study procedures
Endoscopy was performed at screening to evaluate EAI. Patients were treated with once-weekly Adacolumn apheresis over 5 consecutive weeks; this could be extended for up to 10 once-weekly treatments dependent upon treatment response, at the discretion of the investigator. The treatment schedule followed the typical clinical approach for administering Adacolumn apheresis in patients with UC. 18 Each apheresis session was performed at a 30 ml/min flow rate for 60 min, with a final volume of 1.8 l of peripheral venous blood processed per session. Any eventual interruptions of apheresis were not to be included in the 60 min apheresis time period. A decrease in the dose of concomitant steroids was allowed during the study, if tapered down in suitable steps, at the discretion of the investigator.
Study objectives and outcomes
The primary objective of this study was to assess device efficacy, as measured by the primary endpoint of UC remission rate at Additional secondary objectives were to observe and document device safety as measured by: adverse events [AEs] and vital signs at each study visit; laboratory safety parameter changes [haemoglobin, red blood cell counts, white blood cell counts, platelets and coagulation parameters] at screening, baseline, and every treatment visit; and physical examination findings at baseline and Week 12.
Statistical analysis
This interim analysis was performed on all patients enrolled in the ART study who had a baseline visit at least 12 weeks before the data cut-off of 1 July 2013. Only data collected until the end of the 12-week follow-up period were included. Descriptive summaries were generated where appropriate for each of the primary and secondary outcomes. The summary for the primary efficacy variable includes absolute frequencies, rates [percentages], and exact 95% confidence intervals [CIs] for the rates [Pearson-Clopper intervals].
Efficacy endpoints were assessed in the intention-to-treat [ITT] population [defined as all patients with ≥1 treatment and ≥ 1 valid post-baseline CAI measurement] and the per-protocol [PP] population [defined as all patients from the ITT population who received ≥ 5 treatments or who discontinued due to lack of efficacy or due to an AE with at least possible relation to the study device or treatment]. Remission rate at Week 12 was estimated within the ITT and PP populations, calculated by dividing the number of patients with remission by the total number of patients; all missing values were analysed as not showing remission. Time to remission and response and time to steroid-free remission and response were summarised using Kaplan-Meier estimates. The reference range for central calprotectin testing was 0-50 mg/kg. In addition, a 200 mg/kg clinical cut-off level was also used to assess the effects of GMA on calprotectin levels in this interim analysis, as it is generally appreciated that in IBD patients a cut-off level for calprotectin of 50 mg/kg is not appropriate and may not reflect relevant inflammatory activity. The proportions of patients above and below the cut-off of 200 mg/kg were analysed using McNemar's test. Safety endpoints were assessed in the safety population, defined as all patients with ≥ 1 treatment.
All analyses were performed using SAS ® Software Version 9.1.3 or later.
Results
Patient disposition
Patients were enrolled from 12 October 2011. As of the data cut-off date of 1 July 2013, 86 patients were enrolled and signed informed consent, and were included in the total population [ Figure 1b] 
Patient demographics and baseline characteristics
Patient demographics and baseline characteristics of the safety population are shown in Table 1 Clinical activity index ≥ 6 after 3 months of treatment with 2.5 mg/kg azathioprine or 1.5 mg/kg 6-mercaptopurine or after 14 weeks from starting anti-TNF-α therapy. 
Additional secondary efficacy outcomes
Other secondary outcomes at Week 12 included steroid-free remission and response, and CAI and EAI change from baseline [ Table 2 ]. Adacolumn treatment resulted in 22.6% and 35.7% of patients in the ITT population achieving steroid-free remission and response, respectively, at Week 12. These patients also experienced mean reductions in CAI and EAI of 3.4 and 2.2, respectively, at Week 12.
Results were similar between the ITT and PP populations [ Table 2 ].
Time to steroid-free remission and response for the ITT population is shown in Figure 3; Quality of life improved from baseline to Week 12 [ Table 3 ], with reductions in all four parameters of the Short Health Scale. The largest reduction was observed for the 'bowel disease affecting daily activities' parameter, with a mean 22.2% reduction from baseline to Week 12. The results of a repeated measures analysis of covariance model indicated a significant effect in change from baseline for all four parameters [p < 0.0001]. Similar results were observed for the PP population. Table 5 ].
Safety evaluation
Mean changes in haemoglobin from baseline through Week 10 ranged from -0.21 to -0.44 g/dl; however, no clinically significant changes were observed at Week 12 compared with baseline. The number of platelets decreased from baseline at every visit, not exceeding a maximum change of -28.8 x 10 9 /l at Week 7. There were no clinically significant shifts in other laboratory parameters or in vital signs. There were no colectomies during the treatment-emergent period and there was one during the follow-up period.
Discussion
UC is a debilitating chronic disease that often affects young patients. Not all patients respond to biologic therapy, which can be associated with significant side effects. Our 12-week interim results from a large cohort of such UC patients show a treatment benefit with Adacolumn in UC patients with limited other therapeutic options. Nearly 40% of the patients in this trial achieved remission at Week 12 and over half achieved a response; furthermore, 23% of patients achieved steroid-free remission, with 36% achieving steroid-free response. Additional outcomes such as quality of life, CAI, and EAI also improved at Week 12 relative to baseline. The levels of calprotectin, which serve as a marker of inflammation, 20 also decreased over the course of the study. The majority of AEs were of mild or moderate intensity, and no new safety signals were observed.
The results of this interim analysis are consistent with previous studies; a pooled meta-analysis of seven randomised controlled trials showed that response or remission was achieved more often in UC patients treated with GMA [risk reduction 1.41; p = 0.01] than in patients treated with conventional therapy, and that after 12 weeks significantly higher remission rates were observed (risk reduction 1.22 [95% CI 1.04, 1.43]). 12 Another meta-analysis demonstrated a significantly improved response rate (odds ratio 2.88 [95% CI 1.60, 5.18]) and remission rate (odds ratio 2.04 [95% CI 1.36, 3.07]) as a result of GMA apheresis compared with conventional pharmacotherapy in patients with active moderate-to-severe UC. 14 In a systematic review of the clinical trial literature, it was shown that GMA apheresis appears to be of some benefit in moderateto-severe UC, 13 suggesting further randomised controlled trials are required in patients with active disease. In a randomised controlled trial enrolling a moderate-to-severe steroid-dependent/refractory UC population, the non-inferiority of 5 and 10 Adacolumn treatments was established after 12 weeks, with clinical remission observed in 44% and 40% of patients, respectively. 21 These data are in contrast to a randomised trial of Adacolumn, in which patients with moderate-to-severe active UC received either Adacolumn or sham apheresis for 9 weeks. Clinical response was observed in 44% of Adacolumn-treated patients and 39% of sham-treated patients, a difference that was not statistically significant. However, a post hoc analysis found significant differences in clinical remission and response in patients with modified Riley scores of 7, denoting histologically active disease with erosions or ulcerations. 22 This suggests that the effect of apheresis is more apparent in UC patients with active disease. 23 Since other therapies such as anti-TNF-α are associated with risk of serious infections, lymphoma, and associated mortality, 3, 24, 25 the favourable safety profile of Adacolumn as observed in the past and in present studies may therefore be of benefit in these patients. Common fears of patients with ulcerative colitis include adverse events associated with medications, which can affect adherence to treatments. 26, 27 GMA itself is not without adverse events; in previous studies, shivering, nausea, headaches, 'flushing', and fever have been reported in 5-33% of treated patients. 7 The most common treatment-emergent adverse event observed in the present study was headache. Due to the nature of GMA, vascular access adverse events pose a potential problem for treatment administration; in this study, 8.2% of patients experienced vascular access complications, defined as the inability to cannulate or no flow. The events observed in this study were however mild-to-moderate; a non-drug therapy such as Adacolumn with this safety profile may be an attractive option for patients.
The ART population was composed of patients who are difficult to treat and for whom the current clinical guidelines are of less use due to a paucity of therapeutic options. A limitation of this study was the single-arm design, meaning that statistical comparisons could not be performed. A placebo control would have been included under ideal circumstances, but the clinical setting of the patient population provided the rationale for the ART study design, due to the difficulty of performing randomised trials in patients with urgent medical need. Positive data have been produced from clinical trials of anti-TNF-α therapies, with long-term steroid-free remission rates of 26% and 13.3% at 12 months, 3 and vedolizumab every 8 weeks in patients with moderate-to-severe UC which resulted in 12-month remission and steroid-free remission rates of 42% and 31%, respectively. 5 However, despite these data there still exists a sizeable population of patients that require effective treatment because of a lack of response to these drugs; results from the full 96-week ART study will provide insight into the long-term effectiveness of Adacolumn treatment.
In conclusion, Adacolumn treatment provided a positive and safe clinical benefit in terms of UC remission and response after 12 weeks in a difficult-to-treat patient subgroup who have limited effective treatment options.
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